Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Astellas Pharma's fezolinetant wins NICE recommendation for menopause-related vasomotor symptoms via neurokinin B blockade
Small molecule, women's health, neurokinin B receptor antagonist, menopause, vasomotor symptoms - Read more

Bavarian Nordic, Serum Institute of India expand partnership with chikungunya vaccine manufacturing agreement
Manufacturing agreement, vaccine, infectious disease, tech transfer - Read more

Locus Cell, Charles River Laboratories sign MoU to explore cell and gene therapy collaboration in Asia-Pacific
Manufacturing agreement, cell therapy, gene therapy, analytical testing - Read more

The pathway to FDA can be difficult to navigate when precedent is limited, and frameworks are thin.

Facet specializes in helping emerging biotech teams understand what your program must demonstrate, how regulators are likely to evaluate the evidence, and what constitutes a viable, and ultimately, approvable, path forward.

It’s a regulatory strategy that starts where it should: with your science and your goals. Not the other way around.

Book a free 30-minute intro session with Facet → click here

UCB's Bimzelx (bimekizumab) shows Ph3 superiority over AbbVie's Skyrizi in psoriatic arthritis head-to-head trial
Antibody, autoimmune, monoclonal antibody, psoriatic arthritis, IL-17 inhibitor - Read more

Biogen reports positive Ph1 data for salanersen in spinal muscular atrophy, announces Ph3 trial design
Antisense oligonucleotide, neurological, spinal muscular atrophy, survival motor neuron protein, pediatric population - Read more

BridgeBio Pharma's BBP-418 shows positive Ph3 interim results for limb-girdle muscular dystrophy type 2I/R9
Small molecule, neurological, limb-girdle muscular dystrophy, LGMD2I/R9, alpha-dystroglycan - Read more

Solid Biosciences reports positive Ph1/2 interim data for SGT-003 microdystrophin gene therapy in Duchenne muscular dystrophy
Gene therapy, neuromuscular disease, microdystrophin, Duchenne muscular dystrophy, dystrophin-associated protein complex - Read more

ExCellThera's Zemcelpro (dorocubicel) shows positive Ph2 results for high-risk acute leukemias and myelodysplastic syndromes
Cell therapy, cancer, stem cell transplantation, acute leukemia, myelodysplastic syndromes, graft-versus-host disease - Read more

CK Life Sciences establishes Sequencio Therapeutics subsidiary to advance therapeutic cancer vaccine portfolio development
Therapeutic cancer vaccine, oncology, strategic, operational - Read more

Salspera plans $91M IPO to fund phase 3 salmonella-based cancer therapy studies
Cancer, bacteria-based therapy, immunotherapy, clinical-stage - Read more

Vima Therapeutics raises $100M Series B, oral drug for movement disorders
Neurological, small molecule, movement disorders, clinical-stage - Read more

Xenon Pharmaceuticals raises $650M public offering, neuroscience-focused biopharmaceutical company
Neuroscience, drug discovery, clinical-stage, biopharmaceutical - Read more

Dianthus Therapeutics raises $625M public offering, advancing autoimmune disease therapies development
Autoimmune, clinical-stage, next-generation therapies - Read more

BioXcel Therapeutics raises $8M registered direct offering, AI-driven biopharmaceutical neuroscience medicines
Neuroscience, AI-driven, biopharmaceutical, clinical-stage - Read more

Longeveron raises $30M private placement, cellular therapy for rare pediatric conditions
Cell therapy, rare disease, clinical-stage, aging-related conditions - Read more

Eli Lilly invests $3B in China operations to boost orforglipron weight loss pill manufacturing capacity
Small molecule, metabolic disease, strategic, major transaction - Read more

NIH grants generated 250% return on $36.6B investment despite funding delays reducing economic impact by $430M
Government funding, biomedical research, financial, investment - Read more

Agilent Technologies to acquire Biocare Medical for $950M to enhance pathology portfolio and IHC offerings
Monoclonal antibody, oncology, strategic, major transaction - Read more

FDA launches unified Adverse Event Monitoring System replacing fragmented databases, saving $120M over five years
Regulatory, operational, cost reduction, financial - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Evotec launches "Horizon" restructuring plan, cutting 800 jobs and closing four sites by 2027
Drug discovery services, operational, cost reduction, strategic - Read more

CNS Pharmaceuticals divests glioblastoma pipeline berubicin and TPI 287 in strategic pivot to new neurology, oncology targets
Small molecule, oncology, strategic, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here